A questionnaire on prescription patterns of proton pump inhibitors for hemodialysis patients in Japan
Autor: | Masahide Furusho, Sayaka Shimizu, Akio Nakashima, Takeshi Nakata, Hiroo Kawarazaki |
---|---|
Rok vydání: | 2020 |
Předmět: |
Nephrology
Peptic Ulcer medicine.medical_specialty Physiology medicine.medical_treatment Population 030232 urology & nephrology 030204 cardiovascular system & hematology Drug Prescriptions 03 medical and health sciences Deprescriptions 0302 clinical medicine Japan Renal Dialysis Surveys and Questionnaires Physiology (medical) Internal medicine medicine Humans Practice Patterns Physicians' Medical prescription education Dialysis Polypharmacy education.field_of_study business.industry Proton Pump Inhibitors Middle Aged medicine.disease Discontinuation Emergency medicine Gastroesophageal Reflux GERD Antacids Hemodialysis business |
Zdroj: | Clinical and Experimental Nephrology. 24:565-572 |
ISSN: | 1437-7799 1342-1751 |
Popis: | Proton pump inhibitors (PPIs) are widely used in the general population often without an endpoint. The practice of prescribing PPIs in the hemodialysis (HD) population is unknown. Thus, we aimed to identify the practice pattern related to PPI prescription for HD patients in Japan through a questionnaire survey. We conducted a questionnaire survey for physicians engaged in dialysis practice through email. An email was sent to physicians listed in the Japanese Society of Nephrology (JSN) and iHOPE International registry. We received 187 physicians’ answers. One-hundred twelve (60%) physicians would prefer to continuously prescribe PPIs after 8 weeks of treatment for peptic ulcer (PU) or gastroesophageal reflux disease (GERD). The main reason for continuous PPI prescription was the concern for recurrence of PU or GERD. Approximately 20% of physicians responded that they were not accustomed to de-prescribing PPIs for PU or GERD. The reason for PPI de-prescription was the concern for side effects or insurance adaptation period. Even in cases wherein PPIs were prescribed for uncertain reasons, 42% physicians would continuously prescribe PPIs. Most physicians (82%) who answered about stopping PPIs regarded HD patients as a high-risk group for PU. PPI prescription is often continued in HD patients. De-prescription is not a common practice in Japan. It remains unclear whether discontinuation of PPIs should be recommended in hemodialysis patients who have a high risk of gastrointestinal ulcer. Yet, considering the side effects and polypharmacy in the HD population, more discussions on preferable de-prescription of PPIs are needed. |
Databáze: | OpenAIRE |
Externí odkaz: |